Clinical Trials Browser

Phase 2 × INDUSTRY × tafasitamab × Clear all

NCT06465433 2025-12-10

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

Phase 2 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT05328102 2024-04-30

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Phase 2 Terminated

3 enrolled 6 charts

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT01685008 2023-11-07

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Phase 2 Completed

92 enrolled 37 charts

Lymphoma, Non-Hodgkin

NCT02399085 2023-10-23

L-MIND

Phase 2 Completed

81 enrolled 23 charts 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT02639910 2021-12-20

COSMOS

Phase 2 Completed

24 enrolled 13 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01685021 2018-02-22

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

Phase 2 Terminated

22 enrolled 12 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma